DSM-Firmenich AG stock analysis
Want to see NL:DSFIR full AI Analyst Report?
DSM-Firmenich AG (DSFIR) Stock Price & Analysis
DSFIR Stock Chart & Stats
- Day’s Range
- EUR 103.75 - EUR 107.40
- 52-Week Range
- EUR 55.22 - EUR 113.45
- Previous Close
- EUR 109.80
- Volume
- N/A
- Average Volume (3M)
- 598.19K
- Market Cap
- EUR 25.31B
- Enterprise Value
- EUR 25.37B
- Total Cash (Recent Filing)
- EUR 2.31B
- Total Debt (Recent Filing)
- EUR 6.76B
- Price to Earnings (P/E)
- ―
- Beta
- 0.95
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- 0.86
- Last Dividend Ex-Date
- May 11, 2026
- Dividend Yield
- 2.37%
Bulls Say, Bears Say
Bulls Say
Revenue Rebound And Gross-margin Improvement
The strong top-line rebound, together with higher gross margin, indicates improving demand, pricing, product mix, or cost control. If sustained, this combination can strengthen operating leverage and provide a more durable foundation for earnings recovery across the company’s specialty ingredient businesses.
Positive Operating Cash Flow And Free Cash Flow
Substantial operating and free cash flow provides internal funding for research, manufacturing capacity, debt service, and shareholder distributions. Positive cash generation despite reported net losses is a meaningful resilience factor, although its durability depends on eventual improvement in underlying earnings quality.
Diversified Specialty-ingredient Business Model
Exposure to multiple end markets reduces reliance on any single application and broadens opportunities for recurring B2B demand. Formulation expertise, science-based products, application support, and customer integration can deepen relationships and make ingredients more difficult to replace over time.
Bears Say
Persistent Net Losses And Negative Returns
Sustained net losses and negative returns show that recent revenue and gross-margin gains have not translated into attractive shareholder profitability. This weakens retained-earnings growth, limits confidence in earnings power, and makes a durable recovery dependent on restoring positive operating and net margins.
Volatile Earnings And Softer Operating Profitability
The shift from profits to losses over recent periods, alongside a lower EBIT margin, indicates that earnings conversion remains inconsistent. This volatility makes financial planning and capital allocation less predictable and raises the risk that improved revenue and gross margin will not persist through the income statement.
Rising Leverage And Limited Debt Cash-flow Coverage
Leverage remains moderate but has increased, while operating cash flow covers only a portion of total debt. If profitability stays weak, higher obligations could reduce financial flexibility and compete with investment needs, making balance-sheet resilience more dependent on sustained cash generation.
DSM-Firmenich AG News
DSFIR FAQ
What was DSM-Firmenich AG’s price range in the past 12 months?
What is DSM-Firmenich AG’s market cap?
When is DSM-Firmenich AG’s upcoming earnings report date?
How were DSM-Firmenich AG’s earnings last quarter?
Is DSM-Firmenich AG overvalued?
Does DSM-Firmenich AG pay dividends?
What is DSM-Firmenich AG’s EPS estimate?
How many shares outstanding does DSM-Firmenich AG have?
What happened to DSM-Firmenich AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of DSM-Firmenich AG?
What is the TipRanks Smart Score and how is it calculated?
Company Description
DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. The Animal Nutrition & Health segment offers animal proteins, vitamins, performance solutions, and data-driven precision services. The company was founded in 1902 and is based in Kaiseraugst, Switzerland.
- Sector
- General
- Industry
- Chemicals - Specialty
- CEO
- Dimitri de Vreeze
- Employees
- 28,550
- Website
- www.dsm-firmenich.com
- Address
- Wurmisweg 576, Kaiseraugst, AG, 4303, CH
DSM-Firmenich AG (DSFIR) Earnings & Revenues
DSFIR Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 3 | 3 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 12 | 0 | 0 |








